WO1998036745A3 - Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis - Google Patents

Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis Download PDF

Info

Publication number
WO1998036745A3
WO1998036745A3 PCT/US1998/003235 US9803235W WO9836745A3 WO 1998036745 A3 WO1998036745 A3 WO 1998036745A3 US 9803235 W US9803235 W US 9803235W WO 9836745 A3 WO9836745 A3 WO 9836745A3
Authority
WO
WIPO (PCT)
Prior art keywords
incidence
reducing
fatty acids
polyunsaturated fatty
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/003235
Other languages
French (fr)
Other versions
WO1998036745A2 (en
Inventor
Susan E Carlson
Debra L Ponder
Michael B Montalto
Margaret H Dohnalek
John D Benson
David A Borror
David V Diodato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
University of Tennessee Research Foundation
Original Assignee
Abbott Laboratories
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998036745(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/943,576 external-priority patent/US6080787A/en
Priority to BR9807443-1A priority Critical patent/BR9807443A/en
Priority to PL98343902A priority patent/PL343902A1/en
Priority to EP98906580A priority patent/EP1039892B1/en
Priority to CA002281706A priority patent/CA2281706C/en
Priority to NZ337039A priority patent/NZ337039A/en
Priority to AT98906580T priority patent/ATE265207T1/en
Priority to UA99084742A priority patent/UA66354C2/en
Priority to JP53687198A priority patent/JP2001516343A/en
Priority to SK1123-99A priority patent/SK112399A3/en
Priority to HU0300236A priority patent/HUP0300236A3/en
Priority to DE69823548T priority patent/DE69823548T2/en
Application filed by Abbott Laboratories, University of Tennessee Research Foundation filed Critical Abbott Laboratories
Priority to IL15049098A priority patent/IL150490A0/en
Priority to SI9830669T priority patent/SI1039892T1/en
Priority to AU61769/98A priority patent/AU732903B2/en
Priority to HK01102292.0A priority patent/HK1034033B/en
Priority to IL13112698A priority patent/IL131126A/en
Publication of WO1998036745A2 publication Critical patent/WO1998036745A2/en
Anticipated expiration legal-status Critical
Priority to NO994052A priority patent/NO994052L/en
Priority to IL150490A priority patent/IL150490A/en
Publication of WO1998036745A3 publication Critical patent/WO1998036745A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)

Abstract

Enteral formulas that contain long-chain polyunsaturated fatty acids (PUFAs), e.g. arachidonic acid (AA) and docosahexaenoic acid (DHA) essentially free of cholesterol, and a process for making such enteral compositions are described. More particularly, the invention relates to methods for reducing the incidence of necrotizing enterocolitis by administering compositions which provide n-6 and n-3 long chain PUFAs; phospholipids and/or choline. Compositions from egg yolk lipids are presently preferred as they contain n-6 and n-3 long chain PUFAs and are predominantly in a phosphtidylcholine form. This is believed to provide a synergistic effect. Also disclosed is a process of making such a composition that provides improved organoleptic and stability properties.
PCT/US1998/003235 1997-02-21 1998-02-19 Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis Ceased WO1998036745A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
HK01102292.0A HK1034033B (en) 1997-02-21 1998-02-19 Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis
IL13112698A IL131126A (en) 1997-02-21 1998-02-19 Compositions for reducing the incidence of necrotizing enterocolitis and the preparation thereof
DE69823548T DE69823548T2 (en) 1997-02-21 1998-02-19 USE OF MULTIPLE UNSATURATED FATTY ACIDS FOR PREVENTING NEKROTIZING ENTEROKOLITIS
EP98906580A EP1039892B1 (en) 1997-02-21 1998-02-19 Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis
CA002281706A CA2281706C (en) 1997-02-21 1998-02-19 Methods and compositions for reducing the incidence of necrotizing enterocolitis
NZ337039A NZ337039A (en) 1997-02-21 1998-02-19 Use of polyunsaturated fatty acids for reducing the incidence of necrotizing entercolitis
AT98906580T ATE265207T1 (en) 1997-02-21 1998-02-19 USE OF POLYUNSATURATED FATTY ACIDS TO PREVENT NECROTIC ENTEROCOLITIS
UA99084742A UA66354C2 (en) 1997-02-21 1998-02-19 Methods and compositions for reducing incidence of necrotizing enterocolitis
IL15049098A IL150490A0 (en) 1997-02-21 1998-02-19 A process for the production of an enteral formula containing arachidonic acid and/or docosahexaenoic acid in the form of phospholipids and formula obtained by same
PL98343902A PL343902A1 (en) 1997-02-21 1998-02-19 Methods of and compositions for reducing enteritis and colitis morbidity rate
HU0300236A HUP0300236A3 (en) 1997-02-21 1998-02-19 Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis and process for their preparation
BR9807443-1A BR9807443A (en) 1997-02-21 1998-02-19 Processes for reducing the incidence of necrotic enterocolitis in a child and for the production of an enteral formula, and, improved enteral formulas containing arachidonic acid and docosahexaenoic acid and suitable for feeding children.
SK1123-99A SK112399A3 (en) 1997-02-21 1998-02-19 Methods and compositions for reducing the incidence of necrotizing enterocolitis
JP53687198A JP2001516343A (en) 1997-02-21 1998-02-19 Methods and compositions for reducing the incidence of necrotizing enterocolitis
SI9830669T SI1039892T1 (en) 1997-02-21 1998-02-19 Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis
AU61769/98A AU732903B2 (en) 1997-02-21 1998-02-19 Methods and compositions for reducing the incidence of necrotizing enterocolitis
NO994052A NO994052L (en) 1997-02-21 1999-08-23 Methods and compositions to reduce the incidence of necrotizing enterocolitis
IL150490A IL150490A (en) 1997-02-21 2002-06-30 Process for the production of an enteral formula containing arachidonic acid and /or docosahexaenoic acid in the form of phospholipids and the formula obtained by same

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US80470097A 1997-02-21 1997-02-21
US08/804,700 1997-02-21
US82531497A 1997-03-28 1997-03-28
US08/825,314 1997-03-28
US08/943,576 US6080787A (en) 1997-02-21 1997-10-03 Methods for reducing the incidence of necrotizing enterocolitis
US08/943,576 1997-10-03

Publications (2)

Publication Number Publication Date
WO1998036745A2 WO1998036745A2 (en) 1998-08-27
WO1998036745A3 true WO1998036745A3 (en) 2002-10-03

Family

ID=27420004

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/003235 Ceased WO1998036745A2 (en) 1997-02-21 1998-02-19 Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis

Country Status (23)

Country Link
US (1) US6306908B1 (en)
EP (1) EP1039892B1 (en)
JP (1) JP2001516343A (en)
CN (1) CN1200701C (en)
AT (1) ATE265207T1 (en)
AU (1) AU732903B2 (en)
BR (1) BR9807443A (en)
CA (1) CA2281706C (en)
DE (1) DE69823548T2 (en)
DK (1) DK1039892T3 (en)
ES (1) ES2219871T3 (en)
HU (1) HUP0300236A3 (en)
ID (1) ID22744A (en)
IL (1) IL131126A (en)
NO (1) NO994052L (en)
NZ (1) NZ337039A (en)
PL (1) PL343902A1 (en)
PT (1) PT1039892E (en)
RU (1) RU2199317C2 (en)
SK (1) SK112399A3 (en)
TR (1) TR199902023T2 (en)
TW (1) TWI230607B (en)
WO (1) WO1998036745A2 (en)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121165A0 (en) * 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US6180671B1 (en) * 1998-03-10 2001-01-30 Beth Israel Deaconess Medical Center, Inc. Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
DE19836339B4 (en) 1998-08-11 2011-12-22 N.V. Nutricia carbohydrate mix
US20090274660A1 (en) * 1999-08-17 2009-11-05 Immunopath Profile, Inc. Pluripotent therapeutic compositions and uses thereof
US6495599B2 (en) * 2000-04-13 2002-12-17 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses therof
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
JP4771697B2 (en) * 2002-09-24 2011-09-14 サントリーホールディングス株式会社 Composition having an effect of preventing, improving or improving the normal response of cognitive ability
US7323206B1 (en) 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
ATE433674T1 (en) * 2003-06-23 2009-07-15 Nestec Sa INFANT NUTRITIONAL PREPARATION OR FOLLOW-ON MILK
CN1842277A (en) * 2003-06-24 2006-10-04 堪萨斯大学医学中心 infant formula
FI20060154A7 (en) 2003-08-18 2006-05-11 Btg Int Ltd Treatment of neurodegenerative conditions
EP1597978A1 (en) * 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
US8252769B2 (en) * 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
EP1721611A1 (en) * 2005-04-21 2006-11-15 N.V. Nutricia Nutritional supplement with oligosaccharides for a category of HIV patients
CA2570208A1 (en) * 2004-06-22 2005-12-29 N.V. Nutricia Improvement of barrier integrity in hiv patients
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
EP1656839A1 (en) * 2004-11-11 2006-05-17 N.V. Nutricia Nutrition containing lipid blend
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US7303745B2 (en) 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
ATE471665T1 (en) * 2005-04-21 2010-07-15 Nutricia Nv DIETARY SUPPLEMENTS FOR HIV PATIENTS
ES2488128T5 (en) * 2005-04-27 2022-11-15 Nutricia Nv Nutrition with lipids and indigestible saccharides
EP1888081B1 (en) 2005-05-23 2016-12-28 Massachusetts Institute of Technology Compositions containing pufa and methods of use thereof
JP2007063219A (en) * 2005-09-01 2007-03-15 Juntendo Neonatal necrotizing enterocolitis disease prevention agent
EP1776877A1 (en) * 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
US20070166354A1 (en) * 2005-10-26 2007-07-19 Bridget Barrett-Reis Method of reducing the risk of retinopathy of prematurity in preterm infants
US7829126B2 (en) 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
US20070149617A1 (en) * 2005-11-14 2007-06-28 Deckelbaum Richard J Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
ES2537080T3 (en) * 2005-12-23 2015-06-02 N.V. Nutricia Composition comprising polyunsaturated fatty acids, proteins and manganese and / or molybdenum to improve the composition of cell membranes
US20080003330A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Infant formulas for early brain development
US20080003329A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Enriched infant formulas
US7867542B2 (en) * 2006-11-02 2011-01-11 Ach Food Companies, Inc. Non-flammable release composition
CN101801200B (en) 2007-09-17 2014-10-29 康奈尔大学 Branched chain fatty acids for prevention or treatment of gastrointestinal disorders
BRPI0818079B8 (en) 2007-10-09 2021-07-27 Enzymotec Ltd lipid composition
UY31410A1 (en) * 2007-10-30 2009-05-29 COMPOSITION THAT INCLUDES POLYINSATURATED FATTY ACIDS AND ACTIVATED VEGETABLE CARBON
WO2009057121A1 (en) 2007-11-01 2009-05-07 Enzymotec Ltd. Lipid mixture for infant nutrition
US8361534B2 (en) * 2007-12-20 2013-01-29 Abbott Laboratories Stable nutritional powder
JP2011507518A (en) 2007-12-20 2011-03-10 アボット・ラボラトリーズ Stable nutrition powder
EP2100897A1 (en) * 2008-01-30 2009-09-16 BNLfood Investments SARL Lecithin based composition and its use in food
WO2009096772A1 (en) * 2008-02-01 2009-08-06 N.V. Nutricia Composition for stimulating natural killer cell activity
US9737213B1 (en) * 2009-03-24 2017-08-22 Vioptix, Inc. Using an oximeter probe to detect intestinal ischemia
BRPI1014923A2 (en) * 2009-04-01 2015-09-01 Nestec Sa Obesity risk reduction
TW201112967A (en) 2009-09-16 2011-04-16 Abbott Lab Dryblended nutritional powders
TW201121431A (en) 2009-12-01 2011-07-01 Abbott Lab Soy protein-based nutritional formula with superior stability
TWI492744B (en) 2009-12-04 2015-07-21 Abbott Lab Methods of modulating inflammation in preterm infants using carotenoids
EP2509429A1 (en) * 2009-12-08 2012-10-17 Nestec S.A. Infant formula with probiotics and milk fat globule membrane components
NZ601141A (en) 2010-01-19 2014-07-25 Abbott Lab Nutritional formulas containing synbiotics
ES2481865T3 (en) 2010-01-29 2014-07-31 Abbott Laboratories Nutritional emulsions comprising HMB of calcium
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
BR112012018174A2 (en) 2010-01-29 2019-08-27 Abbott Lab aseptically packaged nutritional liquids comprising hmb.
TWI526161B (en) 2010-06-10 2016-03-21 亞培公司 a substantially transparent nutrient solution comprising calcium HMB and soluble protein
EP2397038A1 (en) 2010-06-21 2011-12-21 Abbott Laboratories Early programming of brain function through soy protein feeding
WO2012009426A1 (en) 2010-07-13 2012-01-19 Abbott Laboratories High tolerance infant formula including hydrolyzed protein
EP2422629A1 (en) 2010-08-23 2012-02-29 Abbott Laboratories Methods for enhancing cognition and/or memory using maltodextrins
WO2012027287A1 (en) 2010-08-24 2012-03-01 Abbott Laboratories Nutritional products including pea protein hydrolysates
JP2013535984A (en) 2010-08-24 2013-09-19 アボット・ラボラトリーズ Nutritional products with improved sensory characteristics
CN103384478B (en) * 2010-12-29 2016-11-23 雅培制药有限公司 The method reducing the sickness rate of baby, child or the necrotizing enterocolitis of child, stomachache and short bowel syndrome
BR112013016587A2 (en) 2010-12-31 2016-09-27 Abbott Lab nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
MY191538A (en) 2010-12-31 2022-06-30 Abbott Lab Human milk oligosaccharides to promote growth of beneficial bacteria
CA2822219C (en) 2010-12-31 2020-12-29 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
BR112013016606A2 (en) 2010-12-31 2016-09-27 Abbott Lab processes for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
DK2658399T4 (en) 2010-12-31 2024-03-25 Abbott Lab NUTRITIONAL COMPOSITIONS COMPRISING HUMAN MILK OLIGOSACCHARIDES FOR USE IN THE TREATMENT AND/OR PREVENTION OF ENTERIC ROTAVIRUS INFECTION
MY196432A (en) 2010-12-31 2023-04-10 Abbott Lab Methods Of Using Human Milk Oligosaccharides For Improving Airway Respiratory Health
US20120171166A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
BR112013016903A2 (en) 2010-12-31 2019-09-24 Abbott Lab human milk oligosaccharides to modulate inflammation
WO2013012989A2 (en) 2011-07-19 2013-01-24 The Trustees Of Columbia University In The City Of New York Method and system for production of hydrogen and carbon monoxide
PH12014500185A1 (en) 2011-07-22 2019-10-11 Abbott Lab Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
HK1199607A1 (en) 2011-08-29 2015-07-10 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
WO2013101591A2 (en) 2011-12-29 2013-07-04 Abbott Laboratories Methods for reducing microbial contamination of dryblended powdered nutritional compositions
WO2013101516A1 (en) 2011-12-29 2013-07-04 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using extracted genomic dna
MY168661A (en) 2012-03-27 2018-11-28 Abbott Lab Methods for modulating cell-mediated immunity using human milk oligosaccharides
WO2013170189A1 (en) 2012-05-11 2013-11-14 Abbott Laboratories Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow
DK2708147T3 (en) 2012-09-14 2020-05-18 Abbott Lab PROCEDURES FOR INCREASING BRAIN FUNCTIONALITY USING 2-FUCOSYL-LACTOSE
ES2572831T3 (en) 2012-09-14 2016-06-02 Abbott Laboratories Nutritional compositions for use in methods to modulate corticosterone levels in individuals with psychological stress
EP2708146A1 (en) 2012-09-17 2014-03-19 Abbott Laboratories, Inc. Nutritional composition for pregnant women with a beneficial glucose and insulin profile
WO2014078544A1 (en) 2012-11-14 2014-05-22 Abbott Laboratories Compositions and methods for improving the long term safety of powdered infant formulas
WO2014099904A1 (en) 2012-12-17 2014-06-26 Abbott Laboratories Methods for enhancing motor function, enhancing functional status and mitigating muscle weakness in a subject
CA2893217C (en) 2012-12-18 2017-11-28 Abbott Laboratories Human milk oligosaccharides to ameliorate symptoms of stress
WO2014100022A1 (en) 2012-12-18 2014-06-26 Abbott Laboratories Dietary oligosaccharides to enhance learning and memory
EP2745705A1 (en) 2012-12-18 2014-06-25 Abbott Laboratories Nutritional use of human milk oligosaccharides
CN104853621A (en) 2012-12-20 2015-08-19 雅培制药有限公司 Nutritional formulations for modulating inflammation using human milk oligosaccharides
EP2745708A1 (en) 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Antidepressant effect of ß-hydroxy-ß-methylbutyrate
EP2983526A1 (en) 2013-03-12 2016-02-17 Abbott Laboratories Composition comprising a multifunctional viscosity modifying agent
CN105188417B (en) 2013-03-15 2017-08-08 雅培制药有限公司 Include the alimentation composition of β hydroxyl β methylbutanoic acids calcium, CPP and protein
EP2986158A1 (en) 2013-03-15 2016-02-24 Abbott Laboratories Methods of maintaining and improving muscle function
HK1221119A1 (en) 2013-03-28 2017-05-26 The Trustees Of Columbia University In The City Of New York Reperfusion with omega-3 glycerides promotes donor organ protection for transplantation
TW201524372A (en) 2013-06-10 2015-07-01 Abbott Lab Methods and compositions for enhancing cognitive performance
WO2015048646A1 (en) 2013-09-30 2015-04-02 Abbott Laboratories Protein powder
SG11201502037QA (en) 2013-10-11 2015-05-28 Abbott Lab Nutritional composition for pregnant women with a beneficial glucose and insulin profile
CN103558296B (en) * 2013-10-18 2015-03-04 中国农业大学 Animal source feed raw material identification method based on fatty acid detection
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
WO2015077233A1 (en) 2013-11-19 2015-05-28 Abbott Laboratories Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
EP2888950A1 (en) 2013-12-24 2015-07-01 Abbott Laboratories Methods for treating, preventing, or reducing neuroinflammation or cognitive impairment
WO2015105981A2 (en) 2014-01-09 2015-07-16 Abbott Laboratories Conditional essentiality of hmb
HK1231398A1 (en) 2014-04-08 2017-12-22 Abbott Laboratories Methods for enhancing mucosal innate immune responses to and/or detection of pathogens using human milk oligosaccharides
DE102015101273A1 (en) 2015-01-29 2016-08-04 Eberhard Karls Universität Tübingen Medizinische Fakultät Prophylaxis and treatment of premature birth-related developmental disorders
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis
RU2665947C1 (en) * 2017-07-13 2018-09-05 Атикат Магомедхановна Герейханова Method of treatment of necrotic enterocolitis
WO2020247225A1 (en) 2019-06-07 2020-12-10 Abbott Laboratories Nutritional ingredient with flow and antifoam properties
EP4106794A4 (en) 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd Methods for treating graft versus host disease
IL297038A (en) 2020-04-06 2022-12-01 Abbott Lab Dietary formulations for modulation of airway-induced cytokines
CN112137998A (en) * 2020-10-10 2020-12-29 上海交通大学医学院附属新华医院 Application of an active ingredient in the preparation of a medicine for preventing and treating necrotizing enterocolitis
WO2022177965A1 (en) 2021-02-16 2022-08-25 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin
WO2022226311A1 (en) 2021-04-23 2022-10-27 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and a designed lipid component for improving lung function
WO2022266058A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods and compositions for treating gas
WO2023159093A1 (en) 2022-02-16 2023-08-24 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin
WO2024064327A1 (en) 2022-09-22 2024-03-28 Abbott Laboratories Human milk oligosaccharides for enhancing blood-brain barrier function

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0395865A2 (en) * 1989-05-05 1990-11-07 Clintec Nutrition Company Enteral diet for patients with pulmonary disease
EP0615694A1 (en) * 1993-03-15 1994-09-21 SKW Trostberg Aktiengesellschaft Process to prepare powdered low fat and low cholesterol egg products
WO1996000016A1 (en) * 1994-06-27 1996-01-04 Institut De Recherche Biologique Novel dietetic phospholipid compositions and use thereof as a dietary supplement

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0092121B1 (en) 1982-04-12 1987-12-16 Board Of Regents, The University Of Texas System Methods and compositions for treating gastro-intestinal ulcer diesease
US4670285A (en) 1982-08-06 1987-06-02 The University Of Toronto Innovations Foundation Infant formula
US4784861A (en) 1986-11-24 1988-11-15 Cca Industries, Inc. Weight-control formulation
US5032585A (en) 1987-02-17 1991-07-16 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy
US5043329A (en) 1987-02-17 1991-08-27 Board Of Regents, University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US4918063A (en) * 1987-02-17 1990-04-17 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US4950656A (en) 1987-02-17 1990-08-21 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5000975A (en) 1988-12-29 1991-03-19 American Home Products Corporation Randomized palm oil fat composition for infant formulas
CA2101274C (en) 1991-01-24 1998-12-15 David J. Kyle Microbial oil mixtures and uses thereof
US5658767A (en) 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
DK0784437T3 (en) 1994-10-05 1999-04-19 Milupa Gmbh & Co Kg Phospholipid-containing fat mixture with LCP fatty acids
JPH09201A (en) * 1995-06-23 1997-01-07 Akikuni Yakida Food for inflammatory bowel disease
US5917068A (en) 1995-12-29 1999-06-29 Eastman Chemical Company Polyunsaturated fatty acid and fatty acid ester mixtures free of sterols and phosphorus compounds
US5790138A (en) 1996-01-16 1998-08-04 Monolithic System Technology, Inc. Method and structure for improving display data bandwidth in a unified memory architecture system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0395865A2 (en) * 1989-05-05 1990-11-07 Clintec Nutrition Company Enteral diet for patients with pulmonary disease
EP0615694A1 (en) * 1993-03-15 1994-09-21 SKW Trostberg Aktiengesellschaft Process to prepare powdered low fat and low cholesterol egg products
WO1996000016A1 (en) * 1994-06-27 1996-01-04 Institut De Recherche Biologique Novel dietetic phospholipid compositions and use thereof as a dietary supplement

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. DI LORENZO ET AL.: "Use of L-arginine in the treatment of experimental necrotizing enterocolitis", J. PEDIATR. SURG., vol. 30, no. 2, 1995, pages 235 - 241, XP002066296 *
R.H.T. VAN BEEK ET AL: "nutrition in the neonate.", CURR. OPIN. PEDIATR., vol. 7, no. 2, 1995, pages 146 - 151, XP002066297 *

Also Published As

Publication number Publication date
HUP0300236A2 (en) 2003-06-28
EP1039892B1 (en) 2004-04-28
ID22744A (en) 1999-12-09
NO994052L (en) 1999-10-20
IL131126A0 (en) 2001-01-28
TR199902023T2 (en) 2001-09-21
PL343902A1 (en) 2001-09-10
DE69823548D1 (en) 2004-06-03
DK1039892T3 (en) 2004-08-30
DE69823548T2 (en) 2005-02-24
SK112399A3 (en) 2000-12-11
TWI230607B (en) 2005-04-11
JP2001516343A (en) 2001-09-25
NZ337039A (en) 2001-06-29
NO994052D0 (en) 1999-08-23
IL131126A (en) 2003-04-10
BR9807443A (en) 2000-04-25
HUP0300236A3 (en) 2003-09-29
AU6176998A (en) 1998-09-09
ATE265207T1 (en) 2004-05-15
CA2281706C (en) 2008-08-05
ES2219871T3 (en) 2004-12-01
US6306908B1 (en) 2001-10-23
EP1039892A2 (en) 2000-10-04
CN1200701C (en) 2005-05-11
AU732903B2 (en) 2001-05-03
PT1039892E (en) 2004-09-30
CA2281706A1 (en) 1998-08-27
CN1269718A (en) 2000-10-11
WO1998036745A2 (en) 1998-08-27
HK1034033A1 (en) 2001-10-12
RU2199317C2 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
WO1998036745A3 (en) Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis
AU2002309856B2 (en) Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
Vidgren et al. Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men
AR005556A1 (en) ENTERAL FORMULA, A NUTRITIONAL SUPPLEMENT CONTAINING A COMPOSITION OF TRIGLYCERIDES, TRIGLYCERIDES, AND A PROCEDURE FOR PREPARING FATTY ACID ESTERS FROM A LIPID MIXTURE
DK1121115T4 (en) PUFA supplements
Huang et al. Modification of liver fatty acid metabolism in mice by n− 3 and n− 6 Δ6-desaturase substrates and products
US20040209953A1 (en) Glyceride compositions and methods of making and using same
DE69622722D1 (en) Dietary composition containing fats for the treatment of the metabolic syndrome
Anding et al. Effects of dietary linolenate on the fatty acid composition of brain lipids in rats
DK1027831T3 (en) Stabilized fat composition, process for its preparation and nutritional product containing it
DE502004010652D1 (en) NEW FAT POWDER
Muriana et al. Fatty acid composition and properties of the liver microsomal membrane of rats fed diets enriched with cholesterol
CA2713259C (en) Lecithin based composition and its use in food
JP2537645B2 (en) Nutritional composition having pharmaceutical activity
Singer et al. Changes of arachidonic acid in phosphatidylcholine different from other lipids in kidneys of spontaneously hypertensive rats after feeding a linoleic acid-rich diet
Driss et al. Polyunsaturated fatty acids: drug or food?
JP3608013B2 (en) Antioxidant composition for polyunsaturated fatty acid or polyunsaturated fatty acid-containing oil
Banyal et al. Chapter-6 Lipid Metbolism
Spurvey Production of structured lipids via enzymatic interesterification of gamma-linolenic acid (GLA) and marine oils

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98804372.6

Country of ref document: CN

Ref document number: 131126

Country of ref document: IL

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 337039

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 112399

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2281706

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1998 536871

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999/02023

Country of ref document: TR

Ref document number: PV1999-2968

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/007737

Country of ref document: MX

Ref document number: 1019997007598

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1998906580

Country of ref document: EP

Ref document number: 61769/98

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1999-2968

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1998906580

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997007598

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 61769/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 150490

Country of ref document: IL

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWG Wipo information: grant in national office

Ref document number: 1019997007598

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1998906580

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1999-2968

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1998906580

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)